Circulating bone marrow-derived endothelial progenitor cells: Characterization, mobilization, and therapeutic considerations in malignant disease

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Until recently, tumor vascularization was thought to occur exclusively through angiogenesis. However, recent studies using different animal models of cancer suggested the importance of bone marrow-derived endothelial progenitor cells (EPCs) (i.e. postnatal vasculogenesis) in tumor vascularization and growth. EPCs are present in the peripheral blood, their levels are increased in response to certain signals/cytokines, and they home into the neovascular bed of malignant tissues. Furthermore, at the clinical level, evidence is emerging that changes in EPC levels might predict the efficacy of anticancer drug combinations that include antiangiogenic agents. On the basis of these observations, EPCs have attractive potential diagnostic and therapeutic applications for malignant diseases. In this paper, we review biological features of EPCs and speculate on the utility of these progenitor cells for medical oncology.

Original languageEnglish
Pages (from-to)186-193
Number of pages8
JournalCytometry Part A
Volume73
Issue number3
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Bone Marrow
Antineoplastic Combined Chemotherapy Protocols
Therapeutics
Neoplasms
Angiogenesis Inhibitors
Medical Oncology
Stem Cells
Animal Models
Endothelial Progenitor Cells
Cytokines
Growth

Keywords

  • Angiogenesis
  • Cancer
  • Endothelial progenitor cells
  • Vasculogenesis

ASJC Scopus subject areas

  • Hematology
  • Cell Biology
  • Pathology and Forensic Medicine
  • Biophysics
  • Endocrinology

Cite this

@article{939bfdd4ef3642b8aada36c67a122208,
title = "Circulating bone marrow-derived endothelial progenitor cells: Characterization, mobilization, and therapeutic considerations in malignant disease",
abstract = "Until recently, tumor vascularization was thought to occur exclusively through angiogenesis. However, recent studies using different animal models of cancer suggested the importance of bone marrow-derived endothelial progenitor cells (EPCs) (i.e. postnatal vasculogenesis) in tumor vascularization and growth. EPCs are present in the peripheral blood, their levels are increased in response to certain signals/cytokines, and they home into the neovascular bed of malignant tissues. Furthermore, at the clinical level, evidence is emerging that changes in EPC levels might predict the efficacy of anticancer drug combinations that include antiangiogenic agents. On the basis of these observations, EPCs have attractive potential diagnostic and therapeutic applications for malignant diseases. In this paper, we review biological features of EPCs and speculate on the utility of these progenitor cells for medical oncology.",
keywords = "Angiogenesis, Cancer, Endothelial progenitor cells, Vasculogenesis",
author = "B. D{\"o}me and J. Dobos and J. T{\'o}v{\'a}ri and S. Paku and Gabor Kovacs and G. Ostoros and J. T{\'i}m{\'a}r",
year = "2008",
month = "3",
doi = "10.1002/cyto.a.20480",
language = "English",
volume = "73",
pages = "186--193",
journal = "Cytometry. Part A : the journal of the International Society for Analytical Cytology",
issn = "1552-4922",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Circulating bone marrow-derived endothelial progenitor cells

T2 - Characterization, mobilization, and therapeutic considerations in malignant disease

AU - Döme, B.

AU - Dobos, J.

AU - Tóvári, J.

AU - Paku, S.

AU - Kovacs, Gabor

AU - Ostoros, G.

AU - Tímár, J.

PY - 2008/3

Y1 - 2008/3

N2 - Until recently, tumor vascularization was thought to occur exclusively through angiogenesis. However, recent studies using different animal models of cancer suggested the importance of bone marrow-derived endothelial progenitor cells (EPCs) (i.e. postnatal vasculogenesis) in tumor vascularization and growth. EPCs are present in the peripheral blood, their levels are increased in response to certain signals/cytokines, and they home into the neovascular bed of malignant tissues. Furthermore, at the clinical level, evidence is emerging that changes in EPC levels might predict the efficacy of anticancer drug combinations that include antiangiogenic agents. On the basis of these observations, EPCs have attractive potential diagnostic and therapeutic applications for malignant diseases. In this paper, we review biological features of EPCs and speculate on the utility of these progenitor cells for medical oncology.

AB - Until recently, tumor vascularization was thought to occur exclusively through angiogenesis. However, recent studies using different animal models of cancer suggested the importance of bone marrow-derived endothelial progenitor cells (EPCs) (i.e. postnatal vasculogenesis) in tumor vascularization and growth. EPCs are present in the peripheral blood, their levels are increased in response to certain signals/cytokines, and they home into the neovascular bed of malignant tissues. Furthermore, at the clinical level, evidence is emerging that changes in EPC levels might predict the efficacy of anticancer drug combinations that include antiangiogenic agents. On the basis of these observations, EPCs have attractive potential diagnostic and therapeutic applications for malignant diseases. In this paper, we review biological features of EPCs and speculate on the utility of these progenitor cells for medical oncology.

KW - Angiogenesis

KW - Cancer

KW - Endothelial progenitor cells

KW - Vasculogenesis

UR - http://www.scopus.com/inward/record.url?scp=40049087424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40049087424&partnerID=8YFLogxK

U2 - 10.1002/cyto.a.20480

DO - 10.1002/cyto.a.20480

M3 - Article

C2 - 18000872

AN - SCOPUS:40049087424

VL - 73

SP - 186

EP - 193

JO - Cytometry. Part A : the journal of the International Society for Analytical Cytology

JF - Cytometry. Part A : the journal of the International Society for Analytical Cytology

SN - 1552-4922

IS - 3

ER -